NICE National Institute for Health and Care Excellence

Putting NICE guidance into practice

Resource impact statement: Cancer Drugs Fund technology

Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

Published: October 2016

NICE has recommended osimertinib for use within the Cancer Drugs Fund (CDF) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer in line with the criteria set out in the recommendations.

Osimertinib will be available to the NHS in accordance with the managed access agreement agreed with NHS England. As part of this, NHS England and AstraZeneca have agreed a commercial access agreement that makes osimertinib available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.

The resource impact of osimertinib will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date that the managed access agreement expires (March 2019) or when the results of the data collection as part of the managed access agreement are available, whichever is sooner. The aim of the CDF guidance review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England's Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.

It is estimated that around 400 people per year whose cancer has the T790M mutation have disease that progresses after first-line treatment with an EGFR tyrosine kinase inhibitor.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.